Post-registration experience with divosilimab in patients with secondary progressive multiple sclerosis with recurrence
Introduction . Therapy aimed at eliminating CD20-positive B cells is considered one of the most significant advances in the treatment of multiple sclerosis. Divozilimab is a humanized anti-CD20 monoclonal antibody lacking fucose in its Fc fragment, which enhances its effector properties. Aim . Тo analyze the e...